Skip to main content
Sign In

Christopher Lieu, M.D.

Assistant Professor, Division of Medical Oncology

Fellowship Training
University of Texas MD Anderson Cancer Center
Residency Training
University of Colorado
Medical Schools
MD, Wake Forest University School of Medicine
Undergraduate Schools
BS, University of North Carolina–Chapel Hill
Current Positions
Director, Colorectal Medical Oncology Program
Deputy Director, Cancer Clinical Trials Office
Dr. Lieu joined the University of Colorado School of Medicine faculty as an Assistant Professor of Medicine in July 2011.  He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident.  He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010. 
Dr. Lieu is a member of the Developmental Therapeutics (phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Program.   These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors.  Dr. Lieu is interested in resistance mechanisms to targeted therapy in GI cancers, and he was awarded the Conquer Cancer Foundation Career Development Award and a NIH K23 grant to study targeted therapies in colorectal cancer.  Dr. Lieu is also investigating novel therapeutic strategies to more effectively treat and prevent colorectal cancer in young adults.
Honors and Awards
      Arnold P. Gold Foundation Excellence in Humanism and Teaching Award
Ruth L. Kirschstein National Research Service Award
American Society of Clinical Oncology (ASCO) Young Investigators Award
Conquer Cancer Foundation Merit Award
Paul Calabresi Career Development Award for Clinical Oncology (K12)
Delegate, ASCO/AACR Methods in Clinical Cancer Research
SWOG Young Investigator Award
ASCO Conquer Cancer Foundation Career Development Award
Department of Internal Medicine Rising Stars Award
Selected Publications
  1. Lieu C, Janssen WJ, Saint S, Dhaliwal G.  The tip of the iceberg.  J Hosp Med 2009; 4(5):317-20. PMID: 19504498
  3. O’Bryant C, Lieu C**, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol 2009; 63(3):477-89. PMID: 18509645
  5. Lieu C, Chow L, Pierson A, Eckhardt SG, O’Bryant CL, Morrow M, Tran ZV, Wright JJ, Gore L. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 2009; 27(1):53-62. PMID: 18618082
  7. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis L, Abbruzzese JL, Heymach JV.  Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 2010; 28(3):453-9. PMID: 20008624
  9. Lieu C, Kopetz S.  Src family of protein kinases: a new and promising target for colorectal cancer.  Clin Colorectal Cancer 2010; 9(2):89-94. PMID: 20378502
  11. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.  Cancer 2011: 117(20):4623-32. PMID: 21456008
  13. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ.  Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix.  Ann Oncol 2011; 23(3): 652-8.  PMID: 21653683
  15. Lieu CH, Heymach JV, Overman MJ, Tran H, Kopetz S.  Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis.  Clin Cancer Res 2011; 17(19): 6130-9.  PMID: 21953501
  17. Scott AJ, Leong S, Messersmith WA, Lieu CH.  A Moving Target: challenges in treating BRAF-mutant colorectal cancer.  Colorectal Cancer 2013; 2(3): 197-204.
  19. Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG.  From Bench to Bedside: Examples of lessons learned in the translation of preclinical studies of targeted agents in cancer drug development.  J Nat Cancer Inst 2013; 105(19): 1441-56.  PMID: 24052618
  21. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S.  The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.  PLOS ONE 2013; 8(10):e77117.  PMID: 24143206
  23. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Goldberg RM, Sargent D, Eckhardt SG, Eng, C.  The association of age with survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program.  J Clin Oncol 2014; 32(27): 2975-84. PMID 25002720
  25. Brittain P, Eckhardt SG, Lieu CH. Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer. Current Cancer Therapy Reviews 2014; 10(1):34-38.
  27. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Quao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S.  Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer.  Br J Cancer 2015; doi. 10.1038/bjc.2015.61 [epub ahead of print].  PMID 25688736.
  28.  Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu CH, McManus M, Tan AC, Zheng X, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt SG, Messersmth WA.  A NOTCH1 Gene Copy Number Gain is a Prognostic Indicator of Worse Survival and a Predictive Biomarker to a Notch1 Targeting Antibody in Colorectal Cancer.  Int J Cancer 2015; 138(1): 195-205. PMID: 26152787
  30. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D; National comprehensive cancer network.  Neuroendocrine Tumors, version 1.2015.  J Natl Compr Canc Netw 2015; 13(1): 78-108.  PMID: 25583772
  31. Tai D, Wells K, Arcaroli J, Vanderbilt C, Aisner DL, Messersmith WA, Lieu CH.  Targeting the WNT signaling pathway in cancer therapeutics.  The Oncologist 2015; 20(10):1189-98. PMID: 26306903.  PMCID: PMC4591954
  33. Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG.  Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.  Oncotarget 2015.  doi: 10.18632/oncotarget.5949  PMID: 26439693 
NIH K12 Paul Calabresi Career Development Award for Clinical Oncology
ASCO Cancer Foundation Young Investigators Award
Conquer Cancer Foundation Career Development Award
Cancer League of Colorado Research Award
Hope Foundation SWOG Early Exploration and Development (SEED) Award
NIH K23 CA190849-01A1 

© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.